47 completed, 5 terminated, 4 withdrawn, 3 active not recruiting. 21 Phase 3, 19 Phase 2, 11 Phase 4, 7 Not applicable, 6 Phase 1.
Follow Placebo Nasal spray: new trials by email Literature Review of Placebo Nasal spray trials Research Report on Placebo Nasal spray
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure ALDP001 Nasal Spray, Placebo Nasal spray - Seasonal Allergic Rhinitis (SAR) | Phase 2 | Recruiting | Alixer Nexgen Therapeutics Limited | 164 | 2025-10-17 | 2025-10-22 |
| The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study Live attenuated influenza vaccine, Placebo nasal spray, recombinant hemagglutinin influenza vaccine - Influenza | Phase 4 | Active not recruiting | The University of Hong Kong | 600 | 2025-10-01 | 2026-05-15 |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) Fasedienol Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder (SAD) | Phase 3 | Active not recruiting | VistaGen Therapeutics, Inc. | 238 | 2024-09-16 | 2026-05-22 |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) Fasedienol Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder | Phase 3 | Active not recruiting | VistaGen Therapeutics, Inc. | 238 | 2024-03-28 | 2025-11-26 |
| Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus Intranasal OXT, Placebo nasal spray - Central Diabetes Insipidus (cDI) | Phase 2 | Recruiting | University Hospital, Basel, Switzerland | 112 | 2024-01-08 | 2026-05-06 |
| Intranasal Lidocaine Spray Versus Nasogastric Tube Administration in the Emergency Room Lidocaine 10% Spray, Placebo - Nasogasrtic Tube Insertion | Not applicable | Completed | Ankara City Hospital Bilkent | 120 | 2023-11-01 | 2025-08-05 |
| A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine TNX-1900, Placebo Nasal Spray - Chronic Migraine, Chronic Migraine, Headache | Phase 2 | Completed | Tonix Pharmaceuticals, Inc. | 88 | 2022-12-06 | 2025-02-25 |
| rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19 rSIFN-co Nasal Spray, Placebo Nasal Spray - COVID-19, SARS-CoV-2 Infection | Phase 2 | Completed | Sichuan Huiyang Life Science and Technology Corporation | 188 | 2022-07-01 | 2025-02-25 |
| Oxytocin on Cold Water Task Performance and Recovery Oxytocin nasal spray, Placebo nasal spray - Cold Exposure | Phase 2 | Completed | Florida Institute for Human and Machine Cognition | 17 | 2022-05-20 | 2026-04-03 |
| Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray, Placebo Nasal Spray - Eustachian Tube Dysfunction | Phase 2 | Recruiting | Cedars-Sinai Medical Center | 80 | 2022-04-20 | 2026-03-11 |
| Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome Oxytocin nasal spray, Placebo - Prader-Willi Syndrome | Phase 2 / Phase 3 | Completed | University Hospital, Toulouse | 25 | 2022-04-05 | 2023-06-01 |
| Oxytocin for Oxidative Stress and Inflammation Oxytocin nasal spray, Placebo nasal spray - Oxidative Stress, Inflammation | Phase 2 | Completed | Florida Institute for Human and Machine Cognition | 40 | 2022-02-01 | 2024-02-22 |
| Efficacy and Safety of Azeol Nasal Spray Versus Placebo in the Treatment of Early Symptoms of Common Cold in Adults Azeol spray nasal, Placebo nasal spray - Nasal Congestion | Not applicable | Completed | Larena SAS | 144 | 2021-11-22 | 2023-11-14 |
| PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2 PH94B Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder | Phase 3 | Terminated | VistaGen Therapeutics, Inc. | 228 | 2021-08-30 | 2025-11-24 |
| PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge PH94B Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder | Phase 3 | Completed | VistaGen Therapeutics, Inc. | 224 | 2021-05-24 | 2025-09-12 |
| Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain esketamine nasal spray, placebo nasal spray - Cancer Pain | Phase 2 | Withdrawn | University Hospital, Basel, Switzerland | 2020-11-25 | 2023-10-19 | |
| High Dose Oxytocin Nasal Spray for Treatment of Tinnitus Oxytocin, Placebo nasal spray - Tinnitus | Phase 3 | Terminated | NYU Langone Health | 33 | 2020-01-15 | 2022-10-05 |
| Use of Intranasal Oxytocin During Detoxification of Crack Cocaine Oxytocin nasal spray, placebo nasal spray, Conventional Inpatient Treatment - Cocaine Withdrawal, Cocaine Smoking | Phase 1 / Phase 2 | Completed | Pontificia Universidade Católica do Rio Grande do Sul | 84 | 2018-09-17 | 2026-09-28 |
| Study of Probiotic Potential of Lactobacillus Strains in the Upper Respiratory Tract After Nasal Spray Application Probiotic nasal spray, Placebo nasal spray - Healthy Volunteers, Chronic Rhinosinusitis (Diagnosis) | Not applicable | Unknown | University Hospital, Antwerp | 120 | 2018-06-01 | 2020-04-08 |
| Target Engagement and Response to Oxytocin Oxytocin nasal spray, Social Cognition Skills Training, Health Management - Schizophrenia | Phase 4 | Completed | University of California, Los Angeles | 120 | 2018-01-04 | 2025-03-21 |
Showing 20 of 63. Sign in to see all of them.
Rhinitis, Allergic, Seasonal (11) · Rhinitis, Allergic (6) · Nasal Obstruction (4) · Phobia, Social (4) · Rhinitis (4) · Rhinitis, Allergic, Perennial (3) · Abdominal Pain (2) · Anxiety Disorders (2) · Asthma (2) · Behavior, Addictive (2) · Gastroparesis (2) · Inflammation (2) · Nausea (2) · Pain (2) · Psychological Well-Being (2)
Organon and Co (6) · VistaGen Therapeutics, Inc. (4) · GlaxoSmithKline (3) · University of California, San Francisco (3) · Evoke Pharma (2) · Florida Institute for Human and Machine Cognition (2) · M.D. Anderson Cancer Center (2) · Padagis LLC (2) · Philipps University Marburg (2) · University Hospital, Basel, Switzerland (2) · University of Chicago (2) · Alcon Research (1) · Alixer Nexgen Therapeutics Limited (1) · Amneal Pharmaceuticals, LLC (1) · Ankara City Hospital Bilkent (1)
United States (33) · Germany (6) · Canada (4) · France (4) · China (2) · Netherlands (2) · Norway (2) · Switzerland (2) · Thailand (2) · Argentina (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Czechia (1)
Winfried Rief, Professor (2) · Adam L. Boxer, M.D., Ph.D. (1) · Arthur Wu, MD (1) · Benito Benitez, MD (1) · Benjamin J Cowling, PhD (1) · Christopher S Stauffer, MD (1) · David Hui, MD (1) · Donald Kellerman, PharmD (1) · Ehud Klein, MD. (1) · Elizabeth A Lawson, MD (1) · Gregory Sullivan, MD (1) · J. Moy, MD (1)
PMID 21121983, PMID 21576556, PMID 23331528, PMID 24717794, PMID 25017530, PMID 27401508, PMID 30321655, PMID 31427745, PMID 33732434, PMID 34029521, PMID 35086102, PMID 37142273, PMID 37924856, PMID 38088821, PMID 42082227
2015 (1), 2023 (1), R01AA015596 (1), R33MH107564 (1)